Buy & Sell Halliburton Company (HAL) – Halliburton Company Price Today
Aura AI Summary
Key Stats
- $34.89BMarket Cap
- EnergySector
- -9.25%3M Drawdown
- $40.96BEnterprise Value
- 1.63%Dividend Yield
- 85 daysTypical Hold Time
Halliburton Company (HAL) is currently valued at a market capitalization of $34.89B, with an enterprise value of $40.96B. Over the past 52 weeks, Halliburton Company has traded between a low of $19.59 and a high of $42.89, highlighting its annual price range. Over the past three months, Halliburton Company has recorded a drawdown of -9.25%, reflecting recent price volatility. Halliburton Company offers a dividend yield of 1.63%, with the most recent dividend of $0.17 paid on 04 Mar 26. On average, investors hold Halliburton Company for approximately 85 days, indicating typical investor behavior on the platform.
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Most Recent News
BlackRock's stake in Fagron briefly rises above 3% before dropping below again.
BlackRock, Inc. disclosed two transparency notifications regarding its holdings in Fagron NV. On May 11, 2026, BlackRock's stake in Fagron rose above the 3% threshold, holding 3.01% of voting rights with 2,072,188 shares plus 145,030 financial instru...
Brodsky & Smith investigates fiduciary duty breaches in merger deals of Dominion Energy, Global Business Travel, Webster Financial, and TopBuild.
Brodsky & Smith LLC has announced investigations into whether the boards of Dominion Energy, Global Business Travel Group, Webster Financial, and TopBuild breached their fiduciary duties to shareholders during recent merger agreements. These probes f...
Japanese partner urges caution on Tavneos use amid safety concerns and FDA scrutiny.
Kissei Pharmaceutical, Amgen's Japanese partner, has advised doctors to exercise caution when prescribing Tavneos (avacopan) due to safety concerns, including risks of liver dysfunction. This follows FDA warnings and a proposed withdrawal of Tavneos ...